Pembrolizumab Bulk Immunological Product

Mixed preparation of pembrolizumab (Keytruda) monoclonal antibody for immunotherapy in melanoma and lung cancer. HTS 3002.14.0010 applies to this bulk mixed form containing the antibody with formulation excipients, not for retail. Used in clinical or manufacturing settings.

Import Duty Rates by Country of Origin

Origin CountryMFN RateCh.99 SurchargesTotal Effective Rate
🇨🇳ChinaFreeFree
🇲🇽MexicoFreeFree
🇨🇦CanadaFreeFree
🇩🇪GermanyFreeFree
🇯🇵JapanFreeFree

Alternative Classifications

This product could be classified differently depending on its characteristics or intended use.

3002.14.00Same rate: Free

If no alternative needed

N/A

3822Higher: 10% vs Free

If diagnostic reagent rather than therapeutic

Monoclonal-based diagnostics fall under diagnostic reagents if for lab testing.

3006.92.00Higher: 10% vs Free

If packaged as first-aid kit component

Immunological products in medical kits classify under heading 3006.

Not sure which classification is right?

Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.

Import Tips & Compliance

Include monoclonal antibody sequence data and purity certificates to confirm classification

Adhere to USP <1043> ancillary materials guidelines if excipients are novel

Watch for reclassification if purity exceeds 95% and deemed 'unmixed' per chapter notes

Related Products under HTS 3002.14.00.10

Rituximab Biosimilar Immunological Preparation

A mixed immunological product containing rituximab monoclonal antibodies used for treating non-Hodgkin lymphoma and rheumatoid arthritis. Classified under HTS 3002.14.0010 as it is an immunological product containing monoclonal antibodies, not put up in measured doses or retail packings. It consists of multiple components including the antibody and stabilizers for therapeutic use.

Trastuzumab Emtansine Mixture

Immunological preparation mixing trastuzumab monoclonal antibody with emtansine for HER2-positive breast cancer treatment. Falls under HTS 3002.14.0010 due to monoclonal antibody content in a mixed, non-retail bulk form for hospital use. Includes buffers and stabilizers as mixed components.

Bevacizumab Biosimilar Mixture

Bulk mixed immunological product with bevacizumab monoclonal antibodies targeting VEGF for colorectal cancer therapy. Classified in HTS 3002.14.0010 as a mixed monoclonal immunological product not in retail form. Contains antibody, surfactants, and buffers.

Infliximab Therapeutic Mixture

Mixed immunological preparation containing infliximab monoclonal antibodies for autoimmune diseases like Crohn's. HTS 3002.14.0010 for bulk mixed monoclonal products used in biotech manufacturing. Includes polysorbate and histidine buffers.

Adalimumab Reference Product Bulk

Bulk mixed form of adalimumab (Humira) monoclonal antibody for rheumatoid arthritis treatment. Falls under HTS 3002.14.0010 as mixed immunological product with monoclonal antibodies, supplied for further dilution. Not in measured retail doses.

Nivolumab Immunotherapy Preparation

Mixed nivolumab monoclonal antibody product for PD-1 inhibition in cancer immunotherapy. HTS 3002.14.0010 classification for bulk mixed immunological containing monoclonals for clinical trials. Includes sucrose stabilizer and buffer system.